《亞洲股市》港韓股續跌0.6%-1%跑輸 印度、印尼及菲股升0.5%-1%
美國10月非農就業新增職位創三個月高兼超預期,加上再有藥廠輝瑞(PFE.US)研發新冠口服藥臨床試驗療效顯著,美股繼上周五全面反覆續升0.2%-0.6%齊創紀錄高後,期貨全面反覆回軟,納指一百期貨沽壓最大,報16,286,回吐0.4%。亞太區股市今天個別發展,菲股連日跑贏,承上周五假後重開高收續升1.9%勢,今早高見7,424,現報7,415,續升1%;印尼扭轉上周五回軟勢,報6,615,回升0.5%;泰股續升0.3%報1,631;越南三連升,報1,464,升0.5%。
印度孟買指數長假後復市延續假前回升0.5%勢,報60,385,續升0.5%。台灣及星馬股市續升0.1%-0.5%。上證半日收3,495,反覆回升0.1%;深成半日收14,467,反覆回升近5點。
然而,韓股低見2,930,現報2,938,續跌1%。日本及澳紐股市也反覆跌不足0.2%,其中日經高低見29,735/29,518,現報29,570,反覆續吐40點或0.1%。
港股兩連跌,今天在重磅新經濟股騰訊(00700.HK)/阿里巴巴(09988.HK)與比亞迪(01211.HK)/吉利(00175.HK)跌逾1%-3%、舜宇(02382.HK)吐近6%及藥明生物(02269.HK)續挫逾8%拖累,最多跌236點或近1%低見24,633獲承接,在金融/地產/公用板塊升逾0.5%支撐,跌幅曾收窄至32點,高見24,837,現報24,717,續跌152點或0.6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.